Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLBS1425 + anthracyclin-based chemotherapy
- Development stage
- Unknown
- Lead developer
- Dexa Medica
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
DLBS1425 + anthracyclin-based chemotherapy is a **combination therapy** investigated as a neoadjuvant treatment for stage II and III breast cancer. DLBS1425 is an investigational oral capsule, developed by Dexa Medica Group, tested in combination with intravenous anthracyclin-based regimens such as CAF (cyclophosphamide, doxorubicin, 5-fluorouracil) or CEF (cyclophosphamide, epirubicin, 5-fluorouracil)[1]. Anthracyclines act by damaging DNA and inhibiting topoisomerase II, leading to cell death and reduced proliferation[2][3][4]. DLBS1425’s mechanism of action is under study, and details specific to its molecular target are not public, but it is used with anthracyclines to assess improved efficacy and safety in cancer therapy[1].
- Other names
- DLBS1425DLBS-1425DLBS 1425anthracyclin-based chemotherapyDLBS1425 plus anthracyclin-based chemotherapyDLBS-1425 plus anthracyclin-based chemotherapyDLBS 1425 plus anthracyclin-based chemotherapy
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on DLBS1425 + anthracyclin-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLBS1425 + anthracyclin-based chemotherapy.